JPWO2020047113A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020047113A5 JPWO2020047113A5 JP2021511544A JP2021511544A JPWO2020047113A5 JP WO2020047113 A5 JPWO2020047113 A5 JP WO2020047113A5 JP 2021511544 A JP2021511544 A JP 2021511544A JP 2021511544 A JP2021511544 A JP 2021511544A JP WO2020047113 A5 JPWO2020047113 A5 JP WO2020047113A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- taurinamide
- taurultam
- methylene glycol
- effective period
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024154822A JP2024170590A (ja) | 2018-08-28 | 2024-09-09 | タウロリジン加水分解産物による神経芽細胞腫治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862723618P | 2018-08-28 | 2018-08-28 | |
| US62/723,618 | 2018-08-28 | ||
| PCT/US2019/048592 WO2020047113A1 (en) | 2018-08-28 | 2019-08-28 | Neuroblastoma treatment with taurolidine hydrolysis products |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024154822A Division JP2024170590A (ja) | 2018-08-28 | 2024-09-09 | タウロリジン加水分解産物による神経芽細胞腫治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535163A JP2021535163A (ja) | 2021-12-16 |
| JP2021535163A5 JP2021535163A5 (https=) | 2022-08-30 |
| JPWO2020047113A5 true JPWO2020047113A5 (https=) | 2022-08-30 |
Family
ID=69645349
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511544A Pending JP2021535163A (ja) | 2018-08-28 | 2019-08-28 | タウロリジン加水分解産物による神経芽細胞腫治療 |
| JP2024154822A Pending JP2024170590A (ja) | 2018-08-28 | 2024-09-09 | タウロリジン加水分解産物による神経芽細胞腫治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024154822A Pending JP2024170590A (ja) | 2018-08-28 | 2024-09-09 | タウロリジン加水分解産物による神経芽細胞腫治療 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3843746A4 (https=) |
| JP (2) | JP2021535163A (https=) |
| KR (1) | KR20210050544A (https=) |
| CN (1) | CN113347976A (https=) |
| AU (1) | AU2019330954B2 (https=) |
| CA (1) | CA3111057A1 (https=) |
| WO (1) | WO2020047113A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113226325A (zh) * | 2018-08-31 | 2021-08-06 | 科医公司 | 牛磺罗定对哺乳动物体内表达myc的肿瘤的治疗 |
| CA3140981A1 (en) * | 2019-05-22 | 2020-11-26 | Geistlich Pharma Ag | Oxathiazin compounds for inhibiting gapdh |
| CN116769723B (zh) * | 2023-08-09 | 2023-11-03 | 山东省成体细胞产业技术研究院有限公司 | 一种gd2嵌合抗原受体修饰的t细胞及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602150A (en) * | 1992-10-02 | 1997-02-11 | Research Foundation For Mental Hygiene, Inc. | Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia |
| US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
| US20050096314A1 (en) * | 2001-04-03 | 2005-05-05 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
| CN100519525C (zh) * | 1999-12-06 | 2009-07-29 | 葛兰素集团有限公司 | 芳香砜类及其医疗用途 |
| JP5027369B2 (ja) * | 1999-12-06 | 2012-09-19 | ガイストリッヒ ファーマ アーゲー | 腫瘍を治療する方法 |
| CA2363973C (en) * | 2000-11-28 | 2009-03-10 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| ATE354380T1 (de) * | 2003-02-03 | 2007-03-15 | Polaschegg Hans-Dietrich Dr Te | Zusammensetzung zur prävention von infektionen durch subkutane prothesen |
| US20080177217A1 (en) * | 2004-05-14 | 2008-07-24 | Hans-Dietrich Polaschegg | Taurolidine Formulations and Delivery: Therapeutic Treatments and Antimicrobial Protection Against Bacterial Biofilm Formation |
| ES2377206T3 (es) * | 2006-01-06 | 2012-03-23 | Ed Geistlich Sohne Ag Fur Chemische Industrie | Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam |
| CN103118669B (zh) * | 2010-06-01 | 2016-01-13 | 盖斯特里希医药公司 | 口服药物治疗方法和组合物 |
| WO2013148912A1 (en) * | 2012-03-30 | 2013-10-03 | Novartis Ag | Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma |
| EP3402527B1 (en) * | 2016-01-11 | 2022-09-28 | CorMedix Inc. | Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers |
-
2019
- 2019-08-28 JP JP2021511544A patent/JP2021535163A/ja active Pending
- 2019-08-28 KR KR1020217008971A patent/KR20210050544A/ko not_active Ceased
- 2019-08-28 WO PCT/US2019/048592 patent/WO2020047113A1/en not_active Ceased
- 2019-08-28 AU AU2019330954A patent/AU2019330954B2/en active Active
- 2019-08-28 EP EP19856239.9A patent/EP3843746A4/en active Pending
- 2019-08-28 CA CA3111057A patent/CA3111057A1/en active Pending
- 2019-08-28 CN CN201980071416.3A patent/CN113347976A/zh active Pending
-
2024
- 2024-09-09 JP JP2024154822A patent/JP2024170590A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024102099A5 (https=) | ||
| FI3426285T3 (fi) | Pegyloidun urikaasin formulaatioita ja annoksia | |
| JP2022031772A5 (https=) | ||
| US20210030680A1 (en) | Nanoparticle compositions and methods of use of parp inhibitor for treatment of cancer | |
| CA2359812A1 (en) | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures | |
| DE60133319D1 (de) | Mehrfach beschichete pharmazeutische dosierungsform | |
| JP2005506367A5 (https=) | ||
| JPH0710773B2 (ja) | 一定の放出性及び即時放出性を有する薬物粒子 | |
| CA2867343A1 (en) | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration | |
| KR20140025314A (ko) | 복합 조성물 | |
| WO2021062282A1 (en) | Combination therapy with cgrp antagonists | |
| JP2021535163A5 (https=) | ||
| EP2254570A1 (en) | Combination comprising paclitaxel for treating ovarian cancer | |
| JPH0710772B2 (ja) | 一定の放出性を保持した薬物粒子 | |
| JP2021514380A5 (ja) | 筋障害及び骨障害を処置するための化合物及び組成物 | |
| Northfelt | Treatment of Kaposi’s sarcoma: current guidelines and future perspectives | |
| JPWO2020047113A5 (https=) | ||
| Galanello | Iron chelation: new therapies | |
| JP2007501806A5 (https=) | ||
| FI4255563T3 (fi) | 5’-o-fenyyliasetyyliuridiini ja terapeuttinen käyttö | |
| HRP20251423T1 (hr) | Pripravci olanzapina i postupci upotrebe | |
| JPWO2020047530A5 (https=) | ||
| JP2021535167A5 (https=) | ||
| CN112915101A (zh) | 一种抗肿瘤联合药物组合物及其应用 | |
| KR20230047412A (ko) | 진통 가려움 완화 약학 조성물 및 그 응용 방법 |